NCT03942042View on ClinicalTrials.gov

A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis

PHASE4CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 5, 2019

Primary Completion Date

July 22, 2020

Study Completion Date

July 22, 2020

Conditions
Generalized Pustular PsoriasisErythrodermic Psoriasis
Interventions
DRUG

Ixekizumab

Administered SC

Trial Locations (7)

467-8602

Nagoya City University Hospital, Nagoya

980-8574

Tohoku University Hospital, Sendai

573-1191

Kansai Medical University Hospital, Hirakata

173 8606

Teikyo University Hospital, Itabashi-ku

105-8471

Jikei University School of Medicine, Minato-Ku

160-0023

Tokyo Medical University Hospital, Shinjuku-ku

545-8586

Osaka City University Medical School Hospital, Osaka

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03942042 - A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis | Biotech Hunter | Biotech Hunter